Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.3 EUR | -1.36% |
|
+3.89% | +81.74% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+81.74% | 1.8B | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.98B | |
-24.33% | 19.27B | |
-19.35% | 15.99B | |
-17.95% | 15.66B | |
-48.32% | 14.5B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- NewAmsterdam Pharma Completes Enrollment in Phase 3 Trial of Obicetrapib to Treat Heterozygous Familial Hypercholesterolemia